Grace Therapeutics, Inc GRCE

Healthcare Biotechnology

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

<< Previous

Bullboard Posts

Next >>

(561)
•••

Post by Justhalffullon Sep 05, 2021 4:27pm

304 Views

Post# 33815824

For the record

If you had invested $10,000 on Feb 7 2012, you would now have 245.87. If you need any more evidence about this outfit, you should not be investing in stocks.

<< Previous

Bullboard Posts

Next >>

StockTalk | Gold Report: Junior miners with tangible upside